Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has announced a strategic partnership with Harrow (Nasdaq: HROW), a leading North American eyecare company, to launch an authorized generic version of Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension). The product is designed to treat and relieve bacterial eye infections, addressing a significant need in the ophthalmic medication market.
According to IQVIA data from January 2025, Maxitrol and its generic equivalents generated annual sales of $20.8 million in the United States, indicating substantial market demand for this type of ophthalmic treatment.
Thomas Sammler, Vice President of Commercial Operations at Nordic Pharma, emphasized the significance of this launch: "Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option."
Product Details and Clinical Application
The newly launched authorized generic contains the same active ingredients as Maxitrol: neomycin and polymyxin B sulfates, which are antibiotics that combat bacterial infections, and dexamethasone, a corticosteroid that reduces inflammation in the eye. This combination makes it effective for treating ocular infections accompanied by inflammatory conditions.
The ophthalmic suspension formulation is specifically designed for eye application, delivering the medication directly to the site of infection. This targeted approach helps maximize therapeutic efficacy while minimizing systemic side effects.
Market Impact and Patient Benefits
The introduction of this authorized generic version is expected to increase accessibility to treatment for patients suffering from bacterial eye infections. By offering a more affordable alternative to the branded product, Nordic Pharma aims to reduce the financial burden on patients while maintaining the same quality and efficacy standards.
Bacterial eye infections, if left untreated, can lead to serious complications including corneal damage and vision impairment. Timely and appropriate treatment with effective medications like this generic version of Maxitrol is crucial for preventing such complications and preserving vision.
Corporate Background
Nordic Group B.V. is a privately owned, medium-sized international pharmaceutical company focused on the development and commercialization of specialty products. The company has established a strong presence throughout Europe and has recently expanded globally through strategic acquisitions. Its portfolio spans several therapeutic areas including Eye Care, Rheumatology, and Women's Health.
Nordic Group is part of SEVER Life Sciences, a holding company created in 2019 that brings together three complementary companies offering a range of products, pharmaceutical development services, and delivery technologies.
Nordic Pharma, Inc., as a subsidiary of Nordic Group B.V., leverages its expertise in bringing biotechnology-derived medicines, sterile manufacturing capabilities, and other advanced technologies to the marketplace through partnerships with established global biopharmaceutical companies.
Harrow, Inc. (Nasdaq: HROW), Nordic Pharma's partner in this venture, is a prominent eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow's mission centers on making its portfolio of pharmaceutical products accessible and affordable to millions of patients annually.
Strategic Significance
This launch represents an important step in Nordic Pharma's ongoing strategy to expand its presence in the U.S. pharmaceutical market, particularly in the ophthalmic sector. By partnering with an established eyecare company like Harrow, Nordic Pharma gains valuable market access and distribution capabilities.
The addition of the Maxitrol authorized generic strengthens Nordic Pharma's position in the generic medications landscape and demonstrates the company's commitment to providing cost-effective treatment options for patients with ocular conditions.
